Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascending-dose DS-9231 (TS23) in intermediate-risk acute pulmonary embolism
2017-000552-25Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of TS23 in pulmonary embolism (PE), sponsored by Daiichi Sankyo Co., Ltd. Started May 2017; status: terminated.
02
Drugs
TS23
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on 2017-000552-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000552-25.